TWIST BIOSCIENCE Reports 16.8% Year-Over-Year Increase in Total Revenue for Fourth Quarter of FY2023

☀️Earnings Overview

For the fourth quarter of fiscal year 2023, TWIST BIOSCIENCE ($NASDAQ:TWST) reported total revenue of USD 67.0 million, a 16.8% increase from the same period in the prior year. This information was released on November 17 2023, along with net income of USD -46.2 million, a decrease from USD -51.1 million reported in the corresponding quarter of the previous year.

Analysis

GoodWhale conducted an analysis of TWIST BIOSCIENCE‘s wellbeing and found that the company had an intermediate health score of 4/10 with regard to its cashflows and debt. This indicates that TWIST BIOSCIENCE is likely to sustain future operations in times of crisis. After further review, GoodWhale classified TWIST BIOSCIENCE as a ‘cheetah’ company. This means that the company has achieved high revenue or earnings growth, but is considered less stable due to lower profitability. Given TWIST BIOSCIENCE’s strengths in asset and growth, yet its weakness in dividend and profitability, investors interested in taking on a higher risk profile may be interested in investing in this company. However, more conservative investors may want to look for other companies that have a higher score and more stable performance. It is important for investors to research thoroughly before making any investment decisions. More…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Twist Bioscience. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Twist Bioscience. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Twist Bioscience. More…

Key Ratios Snapshot

Some of the financial key ratios for Twist Bioscience are shown below. More…

Peers

It offers DNA synthesis on a silicon chip, which enables the company to offer its services at a lower cost than its competitors. The company’s competitors include HTG Molecular Diagnostics Inc, Proteome Sciences PLC, and Genedrive PLC.

– HTG Molecular Diagnostics Inc ($NASDAQ:HTGM)

FoundHTG’s cutting-edge molecular diagnostic platform and cancer test portfolio offers clinicians actionable insights to improve patient outcomes. The company’s tests are designed to guide precision cancer treatment decisions by identifying the specific genetic alterations that drive a patient’s tumor.

FoundHTG’s products are available through a global network of distributors and partners. The company’s tests are used in more than 30 countries and have been validated in over 1,000 peer-reviewed publications.

FoundHTG has a market cap of $6.07M and a ROE of -156.17%.

– Proteome Sciences PLC ($LSE:PRM)

Proteome Sciences PLC is a United Kingdom-based company, which is engaged in the business of proteomics. The Company’s primary focus is on the development and application of proteomics technologies for the biomarker discovery, validation and protein profiling across a range of life science research and clinical applications. It operates through two segments: Biomarkers and Protein Analysis. The Biomarkers segment includes the development and commercialization of biomarkers for diagnostics and drug development. The Protein Analysis segment provides contract research services to the pharmaceutical, biotechnology and academic sectors.

– Genedrive PLC ($LSE:GDR)

Genedrive PLC is a molecular diagnostics company. The Company focuses on the development and commercialization of its technology for the diagnosis of infectious diseases and point-of-care testing. It operates through the following segments: Genedrive and Genedrive Asia Pacific. The Genedrive segment comprises the Company’s operations in Europe, the Middle East, Africa and the Americas. The Genedrive Asia Pacific segment comprises the Company’s operations in Asia Pacific.

Summary

Investors may be encouraged by TWIST BIOSCIENCE‘s fourth quarter results for FY2023 which saw a 16.8% increase in revenue to USD 67 million compared to the same period a year prior. Net income was USD -46.2 million, significantly improved from the USD -51.1 million reported in the same period of the previous year. TWIST BIOSCIENCE’s share price moved up the same day, indicating investor confidence in the company. This could be representative of a promising future for TWIST BIOSCIENCE and a strong investment opportunity for investors.